Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 10:14 PM
Ignite Modification Date:
2025-12-24 @ 10:14 PM
NCT ID:
NCT06238635
Brief Summary:
This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.
Detailed Description:
This is a non-randomized, open-label, two-arm phase 2 trial of dostarlimab and cobolimab for participants with metastatic or recurrent cervical cancer who have or have not been treated with immunotherapy previously.
The names of the study drugs involved in this study are:
* Cobolimab (a type of monoclonal antibody)
* Dostarllimab (a type of monoclonal antibody)
The U.S. Food and Drug Administration (FDA) has not approved cobolimab as a treatment for cervical cancer.
The FDA has not approved dostarlimab for cervical cancer but it has been approved for other uses.
The study procedures including, screening for eligibility, treatment visits, blood tests, x-rays, Computerized Tomograph (CT) scans, Magnetic Resonance Imaging (MRI) scans, or Positron Emission Tomograph (PET) scans.
Participants will be followed for up to 7 years.
It is expected that about 66 people will take part in this research study.
GlaxoSmithKline is funding this research study by providing funding and the study drugs.
Study:
NCT06238635
Study Brief:
Protocol Section:
NCT06238635